Neervannan Seshadri

TARS COO Seshadri sells 11,324 shares across 3 days (Mar 17-19) for $772,443.60; stock down 19.1% from 52-week high

Neervannan Seshadri, Chief Operating Officer, executed three separate sales totaling 11,324 shares for $772,443.60 between March 17-19, 2026, at prices ranging from $67.00 to $69.42. This represents an 11.7% reduction in his post-transaction holdings of 85,780 shares. The timing coincides with a period when the stock has declined 19.1% from its 52-week high of $82.51, though it has gained 6.3% over the prior 30 days. Tarsus Pharmaceuticals remains unprofitable (net income of $-12.6M in the latest quarter), though revenue growth has been robust at 146.7% year-over-year. The multiple sales over consecutive business days and the moderate reduction in holdings provide limited signals regarding insider conviction, as the scale of the reduction and the transaction structure do not clearly indicate either concern or confidence.

COO Seshadri sold 8,366 TARS shares at $76.67; holds 70,817 post-sale as stock trades 9.2% below 52-week high

Neervannan Seshadri, Chief Operating Officer, sold 8,366 shares for $641,421.22, reducing his holdings by 10.6% to 70,817 shares. The sale occurred at $76.67 per share, while the stock now trades at $74.90—2.2% below the transaction price and 9.2% below its 52-week high of $82.51. The company remains unprofitable with net income of $-12,585,000.00 in its most recent fiscal year, despite strong revenue growth of 146.7% year-over-year. The timing of this sale—following a +12.0% 30-day gain but occurring when the stock is materially below its recent peak—coincides with the stock's pullback from elevated levels, warranting investor attention to whether management-level liquidity events presage broader confidence shifts.